Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:KERX

Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis

Keryx Biopharmaceuticals logo

About Keryx Biopharmaceuticals Stock (NASDAQ:KERX)

Advanced Chart

Key Stats

Today's Range
$2.97
$3.47
50-Day Range
N/A
52-Week Range
$2.47
$5.98
Volume
2.60 million shs
Average Volume
1.69 million shs
Market Capitalization
$344.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive KERX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KERX Stock News Headlines

LBTI Lithium & Boron Technology, Inc.
2024 Biopharmaceutical Industry Landscape
Critical AI announcement set to ignite AI 2.0
I just put together an urgent new presentation that you need to see right away. In short: I believe we are mere days away from a critical announcement from a key tech leader… One that will officially ignite “AI 2.0” – and potentially send a whole new class of stocks soaring.
Caliway Biopharmaceuticals Co Ltd 6919
XTL Biopharmaceuticals Ltd ADR XTLB
ImmuneOnco Biopharmaceuticals Shanghai Inc (1541)
Q2 2023 Westrock Coffee Co Earnings Call
See More Headlines

KERX Stock Analysis - Frequently Asked Questions

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) released its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to analyst estimates of $29.56 million.

Based on aggregate information from My MarketBeat watchlists, some other companies that Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Bristol Myers Squibb (BMY), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Meta Platforms (META) and Immunomedics (IMMU).

Company Calendar

Last Earnings
11/08/2018
Today
7/18/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KERX
CIK
1114220
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($0.88)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$163.44 million
Net Margins
-96.41%
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-60.05%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.21
Quick Ratio
1.19

Sales & Book Value

Annual Sales
$60.64 million
Price / Sales
5.67
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.12) per share
Price / Book
-28.00

Miscellaneous

Outstanding Shares
102,380,000
Free Float
N/A
Market Cap
$344.00 million
Optionable
Optionable
Beta
2.35
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:KERX) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners